Abstract: The present invention relates to novel catecholamine derivatives of Formula I, to processes for their preparation, pharmaceutical compositions containing them and to their use in therapy.
Type:
Application
Filed:
August 19, 2008
Publication date:
May 14, 2009
Applicant:
H. LUNDBECK A/S
Inventors:
Morten Jorgensen, Benny Bang- Andersen, Ask Puschl, Niels Mork, Jennifer Larsen, Hakan Vilhelm Wikstrom
Abstract: The present invention relates to electroluminescent compounds represented by Chemical Formula (1) L1L1M(Q)m and electroluminescent devices comprising the same as host material. The electroluminescent compound according to the invention, when used as host material of an OLED, noticeably lowers the operation voltage and enhance the power efficiency.
Type:
Application
Filed:
September 5, 2008
Publication date:
March 26, 2009
Applicant:
Gracel Display Inc.
Inventors:
Hyun Kim, Young Jun Cho, Hyuck Joo Kwon, Bong Ok Kim, Sung Min Kim, Seung Soo Yoon
Abstract: Dibenzorhodamine compounds having the structure are disclosed, including nitrogen- and aryl-substituted forms thereof. In addition, two intermediates useful for synthesizing such compounds are disclosed, a first intermediate having the structure including nitrogen- and aryl-substituted forms thereof, and a second intermediate having the structure including nitrogen- and aryl-substituted forms thereof, wherein substituents at positions C-14 to C18 taken separately are selected from the group consisting of hydrogen, chlorine, fluorine, lower alkyl, carboxylic acid, sulfonic acid, —CH2OH, alkoxy, phenoxy, linking group, and substituted forms thereof. The invention further includes energy transfer dyes comprising the dibenzorhodamine compounds, nucleosides labeled with the dibenzorhodamine compounds, and nucleic acid analysis methods employing the dibenzorhodamine compounds.
Type:
Application
Filed:
July 8, 2008
Publication date:
March 12, 2009
Applicant:
Applied Biosystems Inc.
Inventors:
Scott C. BENSON, Joe Y.L. Lam, Steven Michael Menchen
Abstract: The present invention relates to novel catecholamine derivatives of Formula I, to processes for their preparation, pharmaceutical compositions containing them and to their use in therapy.
Abstract: A method of producing an aromatic compound of the following formula (3) comprising reacting a compound of the following formula (1) with an olefin compound of the following formula (2) in the presence of a transition metal complex: (wherein, an Ar1 ring represents an aromatic hydrocarbon ring or aromatic heterocyclic ring, an Ar2 ring represents a heterocyclic ring containing X1 and N*, and the X1 represents a nitrogen atom or carbon atom and the N represents a nitrogen atom connecting via a double bond to either one of two adjacent atoms in the Ar2 ring.) (wherein, R1, R2, R3 and R4 represent each independently a hydrogen atom, an alkyl group having 1 to 10 carbon atoms or an aryl group having 6 to 18 carbon atoms.) (wherein, Ar1, Ar2, X1, N*, R1, R2 and R3 represent the same meanings as described above.).
Type:
Application
Filed:
February 2, 2007
Publication date:
February 12, 2009
Applicants:
SUMITOMO CHEMICAL COMPANY, LIMITED, OSAKA UNIVERSITY
Abstract: The present invention provides a compound of the formula: (IIa); having a reactive functional group M, capable of reacting with a biopolymer, BP, having at least one group capable of reacting with M to form a covalent linkage, to provide a biopolymer derivative of the formula: (IIIa). The biopolymer derivatives of the invention have enhanced ionisability with respect to free 10 biopolymer (Bp) enabling improved analysis of the biopolymer using mass spectrometry. The invention further provides specific examples of compounds formula (IIa), e.g. compounds of formula: (IIa-2a) and (IIa-58a).
Type:
Application
Filed:
September 22, 2005
Publication date:
January 22, 2009
Inventors:
Edwin Mellor Southern, Vladimir Korshun, Mikhail Sergeevich Shchepinov
Abstract: The present invention relates to aromatic compounds of the formula I wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Ra and wherein Ar may also carry 1 or 2 radicals Rb; X is N or CH; Y is O, S, —CH?N—, —CH?CH— or —N?CH—; A is CH2, O or S; E is CR6R7 or NR3; R1 is C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3-C4-alkenyl, formyl or C1-C3-alkylcarbonyl; R1a is H, C2-C4-alkyl, C3-C4-cycloalkyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3-C4-cycloalkyl, or R1a and R2 together are (CH2)n with n being 2 or 3, or R1a and R2a together are (CH2)n with n being 2 or 3; R2 and R2a are independently of each other H, CH3, CH2F, CHF2 or CF3; R3 is H or C1-C4-alkyl; R6, R7 independently of each other are selected from H, C1-C2-alkyl and fluorinated C1-C2-alkyl; and the physiologically tolerated acid addition salts
Type:
Application
Filed:
October 14, 2005
Publication date:
January 8, 2009
Inventors:
Karla Drescher, Andreas Haupt, Liliane Unger, Sean C. Turner, Wilfried Braje, Roland Grandel, Christophe Henry
Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Abstract: The present invention relates to the field of anti-inflammatory substances, and more particularly to novel compounds that act as antagonists of the mammalian adhesion proteins known as selectins. In some embodiments, methods for treating selectin mediated disorders are provided which include administration of compound of Formula I: wherein the constituent variables are defined herein.
Type:
Grant
Filed:
November 9, 2004
Date of Patent:
December 16, 2008
Assignee:
Wyeth
Inventors:
Neelu Kaila, Silvano L. Debernardo, Kristin M. Jantz, Raymond T. Camphausen, Patricia W. Bedard, Adrian Huang
Abstract: The present invention relates to novel benzo[g]quinoline derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.
Abstract: Compounds of formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meaning indicated in the description, are novel effective PDE4 inhibitors.
Abstract: Acene-based compounds that can be used to prepare n-type semiconductor materials are provided with processes for preparing the same. Composites and electronic devices including n-type semiconductor materials prepared from these compounds also are provided.
Type:
Application
Filed:
November 19, 2007
Publication date:
August 7, 2008
Inventors:
Antonio Facchetti, Tobin J. Marks, Zhiming M. Wang
Abstract: A photoresist monomer having a sulfonyl group, a polymer thereof and a photoresist composition containing the same are disclosed. The photoresist monomer is represented by following Formula. wherein, R* is a hydrogen atom or a methyl group, R1 and R2 are independently a C1˜C20 alkyl group, a C4˜C20 cycloalkyl group, a C6˜C20 aryl group or a C7˜C20 arylalkyl group, one of R1 and R2 may not exist, and R1 and R2 can be connected to form a ring.
Type:
Application
Filed:
October 24, 2007
Publication date:
May 1, 2008
Inventors:
Jung-Youl LEE, Geun-Jong Yu, Sang-Jung Kim, Jae-Woo Lee, Deog-Bae Kim, Jae-Hyun Kim
Abstract: A compound having a diphenylanthracene structure at the center and a specific structure substituted with an aryl group at end portions. An organic electroluminescence device comprises a plurality of layers of thin films of organic compounds which comprise a light emitting layer or a plurality of layers comprising a light emitting layer and are disposed between a pair of electrodes and at least one of the layers of thin films of organic compounds comprises the above compound. The compound exhibits excellent efficiency of light emission and heat resistance, has a long life and emits bluish light having excellent purity of color and the organic electroluminescence device comprises the compound and exhibits the same advantageous properties.
Abstract: The present invention is related to an intermediate layer of an organic electroluminescent device comprising an amine derivative substance which may further comprise a functional group capable of forming crosslinks. In particular, the substance may have excellent solubility and can be easily formed into a thin film. Specifically, the thin film may be stable in the solvent and can be easily formed to various thicknesses. Furthermore, the band gaps and LUMO/HOMO values may be easily controlled depending of the characteristics of the hole transporting material, so that an intermediate layer with the desired characteristics may be formed. Accordingly, the introduction of an intermediate layer manufactured using the substance of the present invention as the intermediate layer may result in an organic electroluminescent device having high efficiency and a longer lifespan.
Abstract: A method of determining beryllium or a beryllium compound thereof in a sample, includes providing a sample suspected of comprising beryllium or a compound thereof, extracting beryllium or a compound thereof from the sample by dissolving in a solution, adding a fluorescent indicator to the solution to thereby bind any beryllium or a compound thereof to the fluorescent indicator, and determining the presence or amount of any beryllium or a compound thereof in the sample by measuring fluorescence.
Type:
Grant
Filed:
March 30, 2004
Date of Patent:
October 31, 2006
Assignee:
Los Alamos National Security, LLC
Inventors:
T. Mark McCleskey, Deborah S. Ehler, Kevin D. John, Anthony K. Burrell, Gavin E. Collis, Edel M. Minogue, Benjamin P. Warner
Abstract: Compounds of the general formula I wherein rings B, C, D and E may be present or not and, when present, are combined with A as A+C, A+E, A+B+C, A+B+D, A+B+E, A+C+E, A+B+C+D or A+B+C+D+E, rings B, C and E being aliphatic whereas ring D may be aliphatic or aromatic/heteroaromatic, and wherein X is —(CH2)m—, in which m is an integer 1–3, to form a ring E or, when E is absent, a group R1 bound to the nitrogen atom, wherein R1 is selected from the group consisting of a hydrogen atom, alkyl or haloalkyl groups of 1 to 3 carbon atoms, cycloalkyl(alkyl) groups of 3 to 5 carbon atoms (i.e.
Type:
Grant
Filed:
December 18, 2003
Date of Patent:
February 14, 2006
Assignee:
H. Lundbeck A/S
Inventors:
Håkan Wikström, Durk Dijkstra, Bastiaan Johan Venhuis
Abstract: The invention relates to a novel polymethine dyes containing at least one acylsulfonamido group of the formula (I) in which n, Y, A and R have the meaning given in the claims, and at least one compound of the formulae (a) to (n) given in the claims. The polymethine dyes according to the invention are suitable for use as dyes and/or labels, in particular for staining or labeling biomolecules.
Type:
Grant
Filed:
July 24, 2000
Date of Patent:
February 7, 2006
Assignee:
Bayer CropScience AG
Inventors:
Geert Deroover, Michael Missfeldt, Lydia Simon
Abstract: The present invention provides a compound having a steroid C17,20-lyase inhibitory activity, which is useful as a prophylactic or therapeutic agent of prostatism and tumor such as breast cancer and the like. A compound represented by the formula: wherein R is a hydrogen atom or a protecting group, R1 is a lower alkyl group or a cyclic alkyl group, and ring A and ring B are each an optionally substituted 5-membered or 6-membered ring having an amide bond in the ring, or a salt thereof.
Abstract: A biphenyl derivative having an amino group with or without alkoxy substituent in the biphenyl backbone, and an organic electroluminescent device using the same.
Type:
Grant
Filed:
December 30, 2003
Date of Patent:
October 18, 2005
Assignee:
Samsung SDI Co., Ltd.
Inventors:
Soo-hyoung Lee, Ji-hoon Lee, Sang-yeol Kim, Byung-hee Sohn, Jhun-mo Son
Abstract: This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis.
Type:
Grant
Filed:
February 21, 2003
Date of Patent:
October 11, 2005
Assignee:
Pfizer, Inc.
Inventors:
Philip Albert Carpino, David Andrew Griffith, Bruce Allen Lefker
Abstract: The present invention relates to the field of optical-fluorescent markers, particularly to benzopyrylo-polymethine-based optical-fluorescent markers.
Type:
Grant
Filed:
December 10, 2003
Date of Patent:
August 2, 2005
Assignee:
Dyomics GmbH
Inventors:
Peter Czerney, Matthias Wenzel, Bernd Schweder, Wilhelm Frank
Abstract: The invention relates to novel tetrahydroquinoline compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of various CNS disorders.
Type:
Grant
Filed:
November 16, 2001
Date of Patent:
February 1, 2005
Assignee:
SmithKline Beecham p.l.c.
Inventors:
Steven Mark Bromidge, Stephen Frederick Moss
Abstract: The present invention provides compounds of formula (I) which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine
Type:
Grant
Filed:
December 6, 2000
Date of Patent:
January 18, 2005
Assignee:
Eli Lilly and Company
Inventors:
John Xiaoqiang He, Nicholas Allan Honigschmidt, Todd Jonathan Kohn, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, Kumiko Takeuchi
Abstract: The present invention provides compounds of formula (I) which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.
Type:
Grant
Filed:
September 9, 2002
Date of Patent:
December 28, 2004
Assignee:
Eli Lilly and Company
Inventors:
John Xiaoqiang He, Nicholas Allan Honigschmidt, Todd Jonathan Kohn, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, Kumiko Takeuchi
Abstract: Disclosed herein are bridged perinones/quinophthalones of the general formula (I) or tautomeric forms thereof
where X1, X2, Ar1 Ar2 and B are as described herein and are particularly characterized in that the bridging B is a radical of the formula —T1—W—T2—, where T1 and T2 are independently O or S and W is alkylene, especially C1-C6-alkylene, C6-C10-arylene, especially phenylene or cycloalkylene, which are each optionally substituted or is the radical of the formula (a)
where the phenyl rings are optionally substituted and
A is a radical of the formula O, S, SO, SO2 or CO, optionally substituted alkylene, or optionally substituted cycloalkylene, said alkylene or cycloalkylene being attached to the adjacent phenyl rings itself or else via its substitutents, or
W is a radical of the formulae
where s and t are independently from 1 to 6, the ends of the radical B each being attached to an aromatic carbon atom of the two radicals Ar1
Type:
Grant
Filed:
November 22, 2002
Date of Patent:
December 21, 2004
Assignee:
Bayer Aktiengesellschaft
Inventors:
Christoph Thiebes, Josef-Walter Stawitz, Ulrich Feldhues
Abstract: Disclosed is a material for a light emitting device excellent in color purity, good in light emitting characteristics and excellent in stability, which consists of a compound represented by the following general formula (I):
L&Parenopenst;A)m (I)
wherein A represents a heterocyclic group in which two or more aromatic heterocycles are condensed; m represents an integer of 2 or more, and the heterocyclic groups represented by A may be the same or different; and L represents a connecting group.
Abstract: A biphenyl derivative having an amino group with or without alkoxy substituent in the biphenyl backbone, and an organic electroluminescent device using the same.
Type:
Application
Filed:
December 30, 2003
Publication date:
October 28, 2004
Inventors:
Soo-hyoung Lee, Ji-hoon Lee, Sang-yeol Kim, Byung-hee Sohn, Jhun-mo Son
Abstract: A novel achiral biaryl-type compound and a circular dichroism (CD) color fixing agent are provided. Furthermore, a method for determining an absolute configuration of a chiral compound is carried out by introducing the above achiral biaryl-type compound into the chiral compound.
Abstract: An electroluminescent element is disclosed, comprising an electroluminescent material and a fluorescent substance emitting light having an emission maximum at the wavelength different from that of light emitted from the electroluminescent material upon absorption of the light emitted from the electroluminescent material. A color conversion filter is also disclosed, comprising a fluorescent substance emitting light having an emission maximum at the wavelengths of 400 to 700 nm upon absorption of the light emitted from the electroluminescent material.
Abstract: An improved organophotoreceptor comprises an electrically conductive substrate and a photoconductive element on the electrically conductive substrate wherein the photoconductive element has
Type:
Application
Filed:
June 9, 2003
Publication date:
April 1, 2004
Inventors:
Nusrallah Jubran, Zbigniew Tokarski, Kam W. Law
Abstract: Compounds of the general formula I
and salts thereof with pharmaceutically acceptable acids or bases are disclosed as well as the use of such compounds for the manufacturing of pharmaceutical compositions for the treatment of Parkinson's disease, psychoses, Huntington's disease, impotence, renal failure, heart failure or hypertension. Pharmaceutical compositions and methods of treating Parkinson's disease and schizophrenia are also disclosed.
Type:
Grant
Filed:
October 18, 2002
Date of Patent:
January 27, 2004
Assignee:
Axon Biochemicals B.V.
Inventors:
Håkan Wikström, Durk Dijkstra, Bastiaan Johan Venhuis
Abstract: The present invention provides formulae for fluorescent compounds that have a number of properties which make them uniquely suited for use in sensors of analytes such as saccharides. The advantageous fluorescent properties include favorable excitation wavelengths, emission wavelengths, fluorescence lifetimes, and photostability. Additional advantageous properties include enhanced aqueous solubility, as well as temperature and pH sensitivity. The compound comprises an aryl or a substituted phenyl botonic acid that acts as a substrate recognition component, a fluorescence switch component, and a fluorophore. Fluorescent compounds are described that are excited at wavelengths greater than 400 nm and emit at wavelengths greater than 450 nm, which is advantageous for optical transmission through skin. The fluorophore is typically selected from transition metal-ligand complexes and thiazine, oxazine, oxazone, or oxazine-one as well as anthracene compounds.
Type:
Grant
Filed:
March 30, 2001
Date of Patent:
January 6, 2004
Assignees:
The Regents of the University of California, MiniMed Inc.
Inventors:
Joe H. Satcher, Jr., Stephen M. Lane, Christopher B. Darrow, Douglas R. Cary, Joe Anh Tran
Abstract: Novel “bispolyamine” inhibitor compounds of polyamine transport are disclosed. These compounds are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury. These compounds display desirable activities both for diagnostic and research assays and therapy.
Type:
Grant
Filed:
May 31, 2000
Date of Patent:
November 11, 2003
Inventors:
Nicolaas M. J. Vermeulin, Christine L. O'Day, Heather K. Webb, Mark R. Burns, Donald E. Bergstrom
Abstract: This invention provides compounds of formula 1, having the structure
which are useful as inhibitors of protein tyrosine kinase and are antiproliferative agents.
Type:
Grant
Filed:
December 29, 2000
Date of Patent:
October 28, 2003
Assignee:
Wyeth
Inventors:
Dan M. Berger, Minu D. Dutia, Frenel F. DeMorin, Diane H. Boschelli, Dennis W. Powell, Hwei-Ru Tsou, Allan Wissner, Nan Zhang, Fei Ye, Biqi Wu
Abstract: The invention relates to a substituted 4-trifluoromethyl carbostyril according to formula (I) and is characterised in that the 4-trifluoromethyl carbostyril is provided with an absorption maximum between 350 and 420 nm and a luminescence maximum between 430 and 900 nm. The molecule can be substituted with groups that are useful for complexing metal ions and/or for binding the molecule to relevant groups of a target molecule or a solid supporting material. The carbostyril as described above can inter alia serve as an antenna molecule of a lanthanide complex. Said complexes can be templates and can be brought into contact with a directly bound or free colour molecule which absorbs in the rant of 580-710 nm. Luminescence effects and decay periods can be measured after the contact with a relevant analyte.
Abstract: Compounds of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis
and pharmaceutically acceptable salts thereof,
n is 0 or 1;
x is 0, 1, 2, 3 or 4;
y is 0, 1, 2, 3 or 4, provided that at least one of x and y is other than 0; and optionally one or more carbons of (CH2)x and/or (CH2)y together with additional carbons form a 3 to 7 membered spirocyclic ring;
R1 and R2 are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl;
R3 is H or lower alkyl;
R4 and R7 are as defined herein.
Abstract: The invention includes pharmaceutically active compounds and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for treating or prophylaxis of undesired thrombosis.
Type:
Grant
Filed:
October 27, 2000
Date of Patent:
August 19, 2003
Assignee:
Sunol Molecular Corporation
Inventors:
Jin-An Jiao, Lawrence K. Luepschen, Esperanza L. Nieves, Hing C. Wong, Dean P. Taylor
Abstract: 1 The present invention provides compounds of formula (I) which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.
Type:
Application
Filed:
September 9, 2002
Publication date:
July 10, 2003
Inventors:
John Xiaoqiang He, Nicholas Allan Honigschmidt, Todd Jonathan Kohn, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, Kumiko Takeuchi
Abstract: The present application relates to novel opioid receptor antagonists and agonists, methods of making these compounds, and methods of use thereof.
Type:
Grant
Filed:
March 19, 2002
Date of Patent:
April 22, 2003
Assignee:
Research Triangle Institute
Inventors:
Frank I. Carroll, James B. Thomas, S. Wayne Mascarella
Abstract: The N-oxides of the compounds of formula (I), in which R1, R2, R3, R31, R4, R5, R51 and R6 have the meanings indicated in the description, arm novel active bronchial therapeutics.
Abstract: The invention relates to a process of preparing a discotic liquid crystalline compound by intramolecular oxidative cyclisation of a diaryl compound in an organic solvent in the presence of a strong acid, characterized in that an oxidative agent comprising a chrom(VI)oxide derivative is used, to discotic liquid crystalline compounds obtainable from said process, to liquid crystalline media, (co)polymers or polymer networks with columnar phases comprising said discotic liquid crystalline compounds, and to the use of said discotic liquid crystalline compounds, liquid crystalline media or liquid crystalline (co)polymers with columnar phases for liquid crystal displays, optical elements like polarizers, compensators or colour filters, chemical sensors, charge transport materials, optical storage media, nonlinear optics, decorative pigments, adhesive or synthetic resins with anisotropic mechanical properties.
Abstract: Compounds of formula (I), in which R1, R2, R3, R31, R4, R5, R51 and R6 have the meanings indicated in the description, are novel active bronchial therapeutics.
Abstract: The N-oxides of the compounds of formula (I), in which R1, R2, R3, R31, R4, R5, R51 and R6 have the meanings indicated in the description, are novel active bronchial therapeutics.
Abstract: The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75NTR common neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75NTR comprises, particularly when bound to nerve growth factor, at least two of the following: (1) a first electronegative atom or functional group positioned to interact with Lys34 of nerve growth factor; (2) a second electronegative atom or functional group positioned to interact with Lys95 of nerve growth factor; (3) a third electronegative atom or functional group positioned to interact with Lys88 of nerve growth factor; (4) a fourth electronegative atom or functional group positioned to interact with Lys32 of nerve growth factor; and (5) a hydrophobic moiety which interacts with the hydrophobic region formed by Ile31, Phe101 and Phe86 of nerve growth factor.
Type:
Grant
Filed:
December 8, 1999
Date of Patent:
December 10, 2002
Assignee:
Queen's University at Kingston
Inventors:
Gregory M. Ross, Igor L. Shamovsky, Sandra Marone, Donald F. Weaver, Richard J. Riopelle
Abstract: Compounds of formula I,
in which R1, R2, R3, R31, R4, R5, R51 and R6 have the meanings indicated in the description, are efficacious bronchial therapeutics.